Abstract
AbstractBackgroundA multistate outbreak of e-cigarette, or vaping, product use-associated lung injury (EVALI) occurred in 2019. Because of EVALI’s novelty and severity, the New York City (NYC) Department of Health and Mental Hygiene (DOHMH) prospectively assessed sequelae among NYC residents who received an EVALI diagnosis in 2019.MethodsUsing existing NYC EVALI surveillance data, DOHMH attempted contact with all living residents who received an EVALI diagnosis in 2019 and conducted 3 waves of telephone interviews during April 2020–March 2021. Interview questions were adapted from the Centers for Disease Control and Prevention’s EVALI case report form and validated surveys. Baseline differences between respondents and nonrespondents were assessed with Chi-square and Fisher’s exact tests; clinical and behavioral characteristics and open-ended responses were summarized.ResultsIn 2019, 53 NYC residents received an EVALI diagnosis; 33 (67%), 14 (29%), and 18 (37%) of 49 living residents participated in the first, second, and third interviews, respectively. Interviews occurred after outpatient diagnosis (6%) or hospital discharge (94%), at a median of 8, 11, and 17 months for each wave. Respondents (N = 33) and nonrespondents (N = 16) did not differ by sex, age, hospitalization status or length. Respondents were mostly male (70%), had a median age of 23 years (range: 16–63 years), and all reported using vaping or e-cigarette products (vaping) with tetrahydrocannabinol (88%), nicotine (49%), or cannabidiol (9%) before diagnosis. Respiratory (first and second interviews) and gastrointestinal (third interviews) symptoms were most commonly reported. Sixteen respondents (49%) reported any new diagnosis during follow-up. Fifteen to 29% of respondents reported vaping at each interview; 58%–93% reported recent non-vaped cannabinoid use.ConclusionNYC residents with EVALI reported symptoms throughout the follow-up period, and approximately half reported newly diagnosed health conditions.
Publisher
Cold Spring Harbor Laboratory
Reference21 articles.
1. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping, Products 2020 [updated August 3, 2021. Available from: https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html#map-cases).
2. Update: Interim Guidance for Health Care Professionals Evaluating and Caring for Patients with Suspected E-cigarette, or Vaping, Product Use–Associated Lung Injury and for Reducing the Risk for Rehospitalization and Death Following Hospital Discharge — United States, December 2019
3. A review of toxic effects of electronic cigarettes/vaping in adolescents and young adults;Crit Rev Toxicol,2020
4. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. About Electronic Cigarettes (E-Cigarettes) [Available from: https://www.cdc.gov/tobacco/basic_information/e-cigarettes/about-e-cigarettes.html.
5. Belok SH , Parikh, R. , Bernardo, J. , et al. E-cigarette, or vaping, product use-associated lung injury: a review. Pneumonia 2020(12):12.